Telling IPF from fibrotic hypersensitivity pneumonitis is notoriously tricky — but sphingolipid profiling may change that. A new study found distinct lipid signatures in both blood plasma and exhaled breath condensate that could reliably differentiate the two conditions. A machine learning model using both sample types hit an impressive AUC of 0.906.
Idiopathic pulmonary fibrosis (IPF) and fibrotic hypersensitivity pneumonitis (fHP) are two serious lung diseases that look frustratingly similar on imaging, biopsy, and clinical workup — making accurate diagnosis a real challenge. Researchers presented new data at the CHEST Annual Meeting suggesting that sphingolipid profiling — measuring specific lipid molecules in blood plasma and exhaled breath condensate (EBC) — could offer a reliable, noninvasive way to tell them apart.
The study analyzed samples from 33 IPF patients, 40 fHP patients, and 28 healthy controls. In plasma, two sphingolipid signatures (DHSo and ceramide C24:1) differed significantly between the two disease groups. In EBC, three signatures stood out: sphingomyelin C24:0, ceramide C24:1, and sphingomyelin C16:0. Notably, a single molecule — sphingomyelin C24:0 in EBC — showed strong standalone discriminatory power.
By the Numbers:
Why it matters: An accurate early diagnosis between IPF and fHP is critical — the two diseases have different treatments and prognoses. A validated, noninvasive biomarker test could spare patients from invasive procedures and help clinicians make faster, more confident treatment decisions.
